Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous MK-3475A plus chemotherapy versus intravenous pembrolizumab plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer
CTR20231113Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, sponsored by Merck & Co.. Started Jun 2023; status: active.
02
Drugs
Beyond the preview
Go deeper on CTR20231113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231113.